356 related articles for article (PubMed ID: 26496252)
1. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
[TBL] [Abstract][Full Text] [Related]
4. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
5. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Wang T; Li C; Li X; Zhai J; Wang S; Shen L
Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
[TBL] [Abstract][Full Text] [Related]
6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
7. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
8. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z
Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients.
Rausei S; Lianos GD; Proserpio I; Ruspi L; Galli F; Frattini F; Mangano A; Rovera F; Boni L; Roukos DH; Pinotti G; Dionigi G
Tumori; 2015; 101(5):511-6. PubMed ID: 25908036
[TBL] [Abstract][Full Text] [Related]
12. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
13. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients.
Chen L; Shi Y; Yuan J; Wu Q; Han Y; Qin R; Jia B; Wei B; Wei L; Dai G; Jiao S
Med Oncol; 2014 Sep; 31(9):159. PubMed ID: 25119501
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
Yao Z; Guo H; Yuan Y; Zhao Y; Yao S; Xu Y; Liu L; Liu T; Liu Y; Yang S
J Chemother; 2014 Apr; 26(2):117-21. PubMed ID: 24090813
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer.
Tai Q; Shao H; Liu Y; Li E; Zhao R
J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
18. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
Biffi R; Fazio N; Luca F; Chiappa A; Andreoni B; Zampino MG; Roth A; Schuller JC; Fiori G; Orsi F; Bonomo G; Crosta C; Huber O
World J Gastroenterol; 2010 Feb; 16(7):868-74. PubMed ID: 20143466
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
